Company: BSX
Filing Date: 2025-05-01
Form Type: 10-Q
Source: 0000885725-25-000026
Chunk: 67

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-05-01
Form: 10-Q
Item: Part I, Item 1
Chunk 67
---
12 211—110.01 Deferred tax expenses (benefits)— (47)47—470.03 Adjusted$1,243 $122 $1,121 $0 $1,121 $0.75 

 Three Months Ended March 31, 2024(in millions, except per share data)Income (Loss) Before Income TaxesIncome Tax Expense (Benefit)Net Income (Loss)Net Income (Loss) Attributable to Noncontrolling InterestsNet Income (Loss) Attributable to Boston Scientific Common StockholdersImpact per ShareReported$608 $115 $493 $(1)$495 $0.33 Non-GAAP adjustments:Amortization expense214 29 184 2 182 0.12 Acquisition/divestiture-related net charges (credits)64 (13)77 — 77 0.05 Restructuring and restructuring-related net charges (credits)46 6 40 — 40 0.03 Investment portfolio net losses (gains) and impairments(14)(3)(11)— (11)(0.01)EU MDR implementation costs14 2 12 — 12 0.01 Deferred tax expenses (benefits)— (37)37 — 37 0.02 Adjusted$932 $99 $833 $1 $832 $0.56 

34

Quarterly Results and Business Overview 

The following section describes our net sales and results of operations by reportable segment and business. For additional information on our businesses and product offerings, refer to Item 1. Business of our most recent Annual Report on Form 10-K. 

 Three Months Ended March 31,(in millions)20252024Increase/(Decrease)Endoscopy$673 $642 4.7%Urology633 513 23.5%Neuromodulation271 256 5.8%MedSurg1,577 1,412 11.7%Cardiology2,429 1,872 29.8%Peripheral Interventions656 573 14.4%Cardiovascular3,085 2,445 26.2%Net Sales$4,663 $3,856 20.9%

MedSurg

Endoscopy 

Our Endoscopy business develops and manufactures devices to diagnose and treat